RxDoctor Payments Data

Shireesha Sangineni, MD

Family Medicine · Fayetteville, NCNPI 1578791422

Payments from drug & device makers

$404in general payments, 2019–2025

Across 17 payments — averaging $23.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$180
  • Lilly USA, LLC$62
  • Baxter Healthcare$42
  • Eisai Inc.$39
  • Sanofi-aventis U.S. LLC$27
  • AstraZeneca$22
  • plus $32 from 2 others

What the payments were for

  • Food & beverage$404100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$404 in reported general payments places this provider in the 55th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$173,181
Medicare patients
364
Services billed
2,550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide80$95,836
FarxigaDapagliflozin Propanediol84$76,161
JardianceEmpagliflozin67$55,349
LinzessLinaclotide19$25,071
MounjaroTirzepatide16$20,806
TrulicityDulaglutide21$20,083
EliquisApixaban18$18,754
Breo ElliptaFluticasone/Vilanterol30$15,865
SymbicortBudesonide/Formoterol Fumarate52$14,391
RybelsusSemaglutide14$14,263
JanuviaSitagliptin Phosphate11$13,181
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$9,188
Combivent RespimatIpratropium/Albuterol Sulfate17$8,553
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,333
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$6,603

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$180$110,09994 claims
AstraZenecaFarxiga, Symbicort, Breztri Aerosphere$22$99,741151 claims
Lilly USA, LLCMounjaro, Trulicity$62$40,88937 claims
GSKBreo Ellipta, Trelegy Ellipta$13$24,19843 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Fayetteville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →